Merck's Keytruda shows positive effect in late-sta
Post# of 148295
(Total Views: 241)
Posted On: 07/29/2019 9:28:06 AM
Merck's Keytruda shows positive effect in late-stage TNBC study;
Jul. 29, 2019 8:26 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) perks up 1% premarket on light volume in response to positive results from a Phase 3 clinical trial, KEYNOTE-522, evaluating Keytruda (pembrolizumab), combined with chemo, compared to placebo + chemo as neoadjuvant therapy followed by Keytruda compared to placebo as adjuvant therapy in patients with triple-negative breast cancer (TNBC).
The dual primary endpoints are pathological complete response (pCR) rate up to week 30 and event-free survival up to ~eight years. The estimated completion date is September 2025.
Interim data showed a statistically significant improvement in pCR in the Keytruda cohort compared to chemo alone regardless of PD-L1 status. The study will continue unchanged to assess the survival endpoint.
Good that we have our CTC levels surrogate endpoint!
Jul. 29, 2019 8:26 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) perks up 1% premarket on light volume in response to positive results from a Phase 3 clinical trial, KEYNOTE-522, evaluating Keytruda (pembrolizumab), combined with chemo, compared to placebo + chemo as neoadjuvant therapy followed by Keytruda compared to placebo as adjuvant therapy in patients with triple-negative breast cancer (TNBC).
The dual primary endpoints are pathological complete response (pCR) rate up to week 30 and event-free survival up to ~eight years. The estimated completion date is September 2025.
Interim data showed a statistically significant improvement in pCR in the Keytruda cohort compared to chemo alone regardless of PD-L1 status. The study will continue unchanged to assess the survival endpoint.
Good that we have our CTC levels surrogate endpoint!
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼